The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions
暂无分享,去创建一个
K. Kotulska | S. Jóźwiak | R. Nabbout | J. Ferreira | M. Feucht | A. Jansen | P. Curatolo | A. Macaya | R. Moavero | C. Hertzberg | B. Zonnenberg | P. Dill | J. C. Kingswood | M. Bjørnvold
[1] D. Krueger,et al. Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis , 2015, Annals of neurology.
[2] P. J. Vries,et al. Neurological and neuropsychiatric aspects of tuberous sclerosis complex , 2015, The Lancet Neurology.
[3] O. Witt,et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. , 2014, The Lancet. Oncology.
[4] P. Bruzzi,et al. TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex , 2014, Orphanet Journal of Rare Diseases.
[5] K. Kotulska,et al. EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients - a prospective study of 5 patients. , 2014, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[6] B. Kaplan,et al. Strategies for the management of adverse events associated with mTOR inhibitors. , 2014, Transplantation reviews.
[7] B. Korf,et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] M. Roszkowski,et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. , 2014, Pediatric neurology.
[9] D. Demuth,et al. 318 Real-world assessment of renal involvement in tuberous sclerosis complex (TSC) patients in the United Kingdom (UK) , 2014 .
[10] C. Michel,et al. The Role of Functional Neuroimaging in Pre-Surgical Epilepsy Evaluation , 2014, Front. Neurol..
[11] M. Piccart,et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] H. Weiner,et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. , 2013, Pediatric neurology.
[13] A. Wilfong,et al. Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer , 2014, Epilepsy currents.
[14] D. Krueger,et al. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.
[15] Hope Northrup,et al. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. , 2013, Pediatric neurology.
[16] F. Garaci,et al. Is mTOR inhibition a systemic treatment for tuberous sclerosis? , 2013, Italian Journal of Pediatrics.
[17] K. Kotulska,et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[18] Jian-Guo Zhang,et al. Predictors of seizure freedom after surgical management of tuberous sclerosis complex: A systematic review and meta-analysis , 2013, Epilepsy Research.
[19] S. Jóźwiak,et al. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[20] David Chen,et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.
[21] N. Rensing,et al. Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex , 2013, PloS one.
[22] D. Krueger,et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma , 2013, Neurology.
[23] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[24] P. Curatolo,et al. Send Orders of Reprints at Reprints@benthamscience.org Mtor Inhibitors in Tuberous Sclerosis Complex , 2022 .
[25] S. Jóźwiak,et al. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[26] A. von Eckardstein,et al. Low-Dose Oral Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISSE ADPKD Trial , 2012, PloS one.
[27] E. Thiele,et al. Low glycemic index treatment for epilepsy in tuberous sclerosis complex , 2012, Epilepsy Research.
[28] M. Curran. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. , 2012, Paediatric drugs.
[29] P. Curatolo,et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis , 2011, Epilepsy & Behavior.
[30] J. Manola,et al. Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease , 2011, PloS one.
[31] K. Kotulska,et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[32] D. Franz. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis , 2011, Expert review of anticancer therapy.
[33] J. Swann,et al. Treatment of Infantile Spasms , 2011, Journal of child neurology.
[34] K. Pointon,et al. Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial , 2011, Clinical Cancer Research.
[35] Kelvin A. Yamada,et al. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway , 2011, Epilepsia.
[36] P. Curatolo,et al. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective , 2011, Child's Nervous System.
[37] A. Zwinderman,et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. , 2010, Kidney international.
[38] J. Bissler,et al. Tuberous Sclerosis Complex Renal Disease , 2010, Nephron Experimental Nephrology.
[39] P. Curatolo,et al. Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. , 2010, Pediatric neurology.
[40] P. Curatolo,et al. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[41] O. Devinsky,et al. Refractory epilepsy in tuberous sclerosis: Vagus nerve stimulation with or without subsequent resective surgery , 2009, Epilepsy & Behavior.
[42] A. Cooney,et al. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles , 2009, Human molecular genetics.
[43] L. James Willmore,et al. Vigabatrin: 2008 Update , 2009, Epilepsia.
[44] S. Jóźwiak,et al. Tuberous sclerosis , 2008, The Lancet.
[45] Vincent J Schmithorst,et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.
[46] E. Kossoff,et al. Tuberous Sclerosis Complex and the Ketogenic Diet , 2005, Epilepsia.
[47] S. Segal,et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] J. Osborne,et al. The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[49] K. Kotulska,et al. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[50] J. Stockman,et al. Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .
[51] A. Ouweland,et al. Missense mutations to the TSC1 gene cause tuberous sclerosis complex , 2009, European Journal of Human Genetics.
[52] H. Zincke,et al. Update on tuberous sclerosis complex. , 2001, Contributions to nephrology.